Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA2 | P00918 | 1/20 | 0.40 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.39 |
| ▸ | POLB | P06746 | 2/20 | 0.39 |
| ▸ | GPR55 | Q9Y2T6 | 1/20 | 0.39 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.38 |
| ▸ | CLK1 | P49759 | 2/20 | 0.38 |
| ▸ | PLCG1 | P19174 | 1/20 | 0.38 |
| ▸ | TXNRD1 | Q16881 | 1/20 | 0.36 |
| ▸ | PPARA | Q07869 | 1/20 | 0.36 |
| ▸ | EGFR | P00533 | 1/20 | 0.36 |
| ▸ | ERBB2 | P04626 | 1/20 | 0.36 |
| ▸ | GRK2 | P25098 | 1/20 | 0.35 |
| ▸ | MMP1 | P03956 | 1/20 | 0.35 |
| ▸ | MMP13 | P45452 | 1/20 | 0.35 |
| ▸ | APLNR | P35414 | 2/20 | 0.35 |
| ▸ | HSD17B3 | P37058 | 1/20 | 0.35 |
| ▸ | BACE1 | P56817 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL830177 | 0.86 | MEN1 (0.42) | CA2L3MBTL1POLBCLK1PLCG1 | |
| SCHEMBL830994 | 0.84 | GCKR (0.42) | L3MBTL1POLBPLCG1 | |
| SCHEMBL830154 | 0.83 | CA2 (0.49) | CA2L3MBTL1POLBHDAC1PLCG1 | |
| SCHEMBL830889 | 0.81 | PARK7 (0.41) | CA2L3MBTL1POLBPLCG1TXNRD1 | |
| SCHEMBL830291 | 0.80 | CA2 (0.37) | CA2POLBGPR55CLK1 | |
| SCHEMBL831283 | 0.80 | CA2 (0.37) | CA2POLBGPR55CLK1 | |
| SCHEMBL830292 | 0.80 | CA2 (0.37) | CA2POLBGPR55CLK1 | |
| SCHEMBL830672 | 0.79 | SULT1A1 (0.43) | CA2L3MBTL1HDAC1PLCG1 | |
| SCHEMBL830871 | 0.79 | MEN1 (0.42) | CA2L3MBTL1POLBPLCG1TXNRD1 | |
| SCHEMBL830426 | 0.78 | PIM1 (0.46) | POLBGPR55HDAC1CLK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8143428-B2 | Heteroaryl sulfones and sulfonamides and therapeutic uses thereof | TEMPLE UNIVERSITY-OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION (US) | 2012-03-27 | — | — | US | claimed |
| US-20070232649-A1 | Heteroaryl Sulfones and Sulfonamides and Therapeutic Uses Thereof | TEMPLE UNIVERSITY-OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION (US) | 2007-10-04 | — | — | US | claimed |
| EP-1765804-A2 | HETEROARYL SULFONES AND SULFONAMIDES AND THERAPEUTIC USES THEREOF | Temple University of the Commonwealth System of Higher Education (US) | 2007-03-28 | — | — | EP | claimed |
| WO-2005123077-A2 | HETEROARYL SULFONES AND SULFONAMIDES AND THERAPEUTIC USES THEREOF | TEMPLE UNIVERSITY-OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION (US) | 2005-12-29 | — | — | WO | claimed |
| US-8143428-B2 | Heteroaryl sulfones and sulfonamides and therapeutic uses thereof | TEMPLE UNIVERSITY-OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION (US) | 2012-03-27 | — | — | US | disclosed |
| US-20070232649-A1 | Heteroaryl Sulfones and Sulfonamides and Therapeutic Uses Thereof | TEMPLE UNIVERSITY-OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION (US) | 2007-10-04 | — | — | US | disclosed |
| EP-1765804-A2 | HETEROARYL SULFONES AND SULFONAMIDES AND THERAPEUTIC USES THEREOF | Temple University of the Commonwealth System of Higher Education (US) | 2007-03-28 | — | — | EP | disclosed |
| WO-2005123077-A2 | HETEROARYL SULFONES AND SULFONAMIDES AND THERAPEUTIC USES THEREOF | TEMPLE UNIVERSITY-OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION (US) | 2005-12-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070232649-A1 | Heteroaryl Sulfones and Sulfonamides and Therapeutic Uses Thereof | SULT1E1, STS, CCNE1 | CA2 2552/4885L3MBTL1 2204/4885POLB 1858/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.